Cargando…
Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
RATIONALE: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626305/ https://www.ncbi.nlm.nih.gov/pubmed/28953662 http://dx.doi.org/10.1097/MD.0000000000008159 |
_version_ | 1783268525022904320 |
---|---|
author | Abramavicius, Silvijus Velickiene, Dzilda Kadusevicius, Edmundas |
author_facet | Abramavicius, Silvijus Velickiene, Dzilda Kadusevicius, Edmundas |
author_sort | Abramavicius, Silvijus |
collection | PubMed |
description | RATIONALE: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxicity is suspected and intravenous methylprednisolone is co-administrated. PATIENT CONCERNS: A 74-year-old woman presented with spontaneous retro-bulbar pain, eyelid swelling and inconstant diplopia. DIAGNOSES: Thyrotoxicosis and severe GO with suspected optic nerve damage and drug induced liver injury (DILI). INTERVENTIONS: Intravenous methylprednisolone pulse therapy was administered to treat GO and methimazole was continued for thyrotoxicosis. Dose of methimazole was reduced after exclusion of concurrent infection and active liver disease. OUTCOMES: The GO symptoms (eyelid swelling, sight loss, proptosis, retro-bulbar pain, diplopia) markedly decreased after the treatment course. Liver transaminases spontaneously returned to normal ranges and remained normal during the next 12 months until the Graves’ disease until the treatment was completed. LESSONS: 1. The interaction of methimazole and methylprednisolone may result in DILI. 2. In a patient without concomitant liver diseases MP can be continued if the methimazole dose is reduced if no other treatment options are available. |
format | Online Article Text |
id | pubmed-5626305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-56263052017-10-11 Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report Abramavicius, Silvijus Velickiene, Dzilda Kadusevicius, Edmundas Medicine (Baltimore) 4200 RATIONALE: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxicity is suspected and intravenous methylprednisolone is co-administrated. PATIENT CONCERNS: A 74-year-old woman presented with spontaneous retro-bulbar pain, eyelid swelling and inconstant diplopia. DIAGNOSES: Thyrotoxicosis and severe GO with suspected optic nerve damage and drug induced liver injury (DILI). INTERVENTIONS: Intravenous methylprednisolone pulse therapy was administered to treat GO and methimazole was continued for thyrotoxicosis. Dose of methimazole was reduced after exclusion of concurrent infection and active liver disease. OUTCOMES: The GO symptoms (eyelid swelling, sight loss, proptosis, retro-bulbar pain, diplopia) markedly decreased after the treatment course. Liver transaminases spontaneously returned to normal ranges and remained normal during the next 12 months until the Graves’ disease until the treatment was completed. LESSONS: 1. The interaction of methimazole and methylprednisolone may result in DILI. 2. In a patient without concomitant liver diseases MP can be continued if the methimazole dose is reduced if no other treatment options are available. Wolters Kluwer Health 2017-09-29 /pmc/articles/PMC5626305/ /pubmed/28953662 http://dx.doi.org/10.1097/MD.0000000000008159 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0 |
spellingShingle | 4200 Abramavicius, Silvijus Velickiene, Dzilda Kadusevicius, Edmundas Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report |
title | Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report |
title_full | Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report |
title_fullStr | Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report |
title_full_unstemmed | Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report |
title_short | Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report |
title_sort | methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: case report |
topic | 4200 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626305/ https://www.ncbi.nlm.nih.gov/pubmed/28953662 http://dx.doi.org/10.1097/MD.0000000000008159 |
work_keys_str_mv | AT abramaviciussilvijus methimazoleinducedliverinjuryovershadowedbymethylprednisolonepulsetherapycasereport AT velickienedzilda methimazoleinducedliverinjuryovershadowedbymethylprednisolonepulsetherapycasereport AT kaduseviciusedmundas methimazoleinducedliverinjuryovershadowedbymethylprednisolonepulsetherapycasereport |